According to American Pregnancy Association (APA) report of 2016, Amniocentesis test is to be 99.4% accurate. There are various types of needles available for amniocentesis test such as 20 G (gauge), 21 G, and 22 G to 29 G. The most suitable needle for the use of amniocentesis test is 20 G to 22 G for the normal Body Mass Index (BMI) of a pregnant woman that is from 18.5 kg/m2 to 24.9 kg/m2. Maximum maternity hospitals recommend mothers to take amniocentesis test, who are aged 35 years and above. According to a data published in UT Southwestern Medical Centre in 2017, women over age 35 years are at higher risk for giving birth to a child with Down syndrome.

Increasing rate of child-birth is significantly driving the global amniocentesis needle market growth. The rising rate of childbirths also requires prenatal diagnosis to know about the health of child. Amniocentesis test reveals every information regarding the fetus such as sex, genetic abnormality, and blood disorder. For instance, Centers for Disease Control and Prevention (CDC) reported in 2017, 3.9 million live child-birth occurred in the U.S.

Free Request Sample Copy of This Report: https://www.coherentmarketinsights.com/insight/request-sample/2624

The global amniocentesis needle market size is expected to increase, owing to merger and acquisitions of major manufacturers of amniocentesis companies. Major companies in the industry are working on acquiring the product portfolios of other companies to increase their market share. For instance, in April 2016, Cooper Surgical, acquired Genesis Genetics, a genetics laboratory specializing in pre-implantation genetic screening (PGS) and pre-implantation genetic diagnosis (PGD) used during the in-vitro fertilization (IVF) process.

The Cooper Surgical is continuously expanding its business in women’s health portfolio. For instance, in November 2016, Cooper Surgical acquired Wallace, the in-vitro fertilization (IVF) segment of Smiths Medical, a division of Smiths Group plc, for a purchase price of around US $168 million to strengthen product portfolio and takeover premier products for women’s health.

North America is expected to hold a dominant position in the global amniocentesis needles market, owing to increasing number of tests performed annually. According to the data of Health Research Funding Organization, over 200,000 amniocentesis tests are performed annually in the U.S.

Europe amniocentesis needles market is expected to foresee a rapid growth during the forecast period, owing to the rising government initiatives and reimbursements policies for amniocentesis tests. According to the data published in Patients Platform Limited in 2016, annually around 5% of the pregnant women (approximately 30,000 women in the U.K.) are offered an invasive, prenatal diagnostic test, usually either amniocentesis or chorionic villus sampling (CVS) for free of cost.

Get PDF Brochure of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/2624

Key players operating in the global amniocentesis needles market include Becton, Dickinson and Company, Biopsybell S.R.L., Cook Medical Inc, CooperSurgical Inc., Integra Lifesciences, Laboratoire CCD, Medline Industries Inc., Medtronic Plc, RI.MOS. S.R.L., Rocket Medical Plc., Smiths Medical Inc., and Tsunami Medical S.R.L.